永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

休市中 08-08 16:08:04

4.270

+0.070

+1.67%

最高4.270	最低4.160	成交量46.60万
今开4.210	昨收4.200	日振幅2.62%
总市值21.97亿	流通市值21.97亿	总股本5.15亿
成交额196.24万	换手率0.09%	流通股本5.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":4.27,"timestamp":1754640484203,"preClose":4.2,"halted":0,"volume":466000,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.39663811847176766,"marketStatus":"休市中","change":0.07,"latestTime":"08-08 16:08:04","open":4.21,"high":4.27,"low":4.16,"amount":1962390,"amplitude":0.02619,"askPrice":4.27,"askSize":1000,"bidPrice":4.2,"bidSize":32000,"shortable":0,"etf":0,"ttmEps":-0.39663811847176766,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1754875800000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":4.2,"openAndCloseTimeList":[[1754616600000,1754625600000],[1754629200000,1754640000000]],"volumeRatio":1.2635574832513612,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2558508550","title":"26家创新药公司完成新一轮融资！","url":"https://stock-news.laohu8.com/highlight/detail?id=2558508550","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558508550?lang=zh_cn&edition=full","pubTime":"2025-08-09 07:17","pubTimestamp":1754695052,"startTime":"0","endTime":"0","summary":"根据药明康德数据库统计，截至2025年7月31日，2025年7月全球生物医药领域共计完成152起融资活动，累计公开披露的融资总额超过了43亿美元。其中，有26家专注于开发创新疗法的公司完成的单笔融资额突破了5000万美元大关。CoRegen：细胞疗法研发公司7月9日，CoRegen宣布完成9339万美元的融资。Nuclidium：放射性治疗和诊断药物研发公司7月10日，Nuclidium宣布成功完成7900万瑞士法郎B轮融资，用于推进铜基放射性药物平台临床开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809072255a6dbb9f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809072255a6dbb9f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","02592","BK1161","09887"],"gpt_icon":0},{"id":"2558057409","title":"创新药基金霸屏“翻倍基” 机构预判创新药企价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2558057409","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558057409?lang=zh_cn&edition=full","pubTime":"2025-08-09 02:45","pubTimestamp":1754678703,"startTime":"0","endTime":"0","summary":"据Wind数据统计，截至8月5日，港股创新药主题基金、指数基金霸屏“翻倍基”榜单。13只“翻倍基”押注创新药据Wind数据统计，截至8月5日，年内复权单位净值增长率达到100%以上的基金合计13只，全员“押注”医药，尤其是港股创新药。除了主动权益基金外，还有多只港股创新药ETF占据了“翻倍基”大部分剩余席位。同时国家出台支持创新药发展以及集采优化，行业板块估值有望实现从“集采折价”到“创新溢价”的转变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809041439973c7f5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809041439973c7f5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","BK1161","06978","01877","BK1583","BK1574","BK1515"],"gpt_icon":0},{"id":"2557573344","title":"永泰生物-B拟8月20日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2557573344","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557573344?lang=zh_cn&edition=full","pubTime":"2025-08-08 22:20","pubTimestamp":1754662856,"startTime":"0","endTime":"0","summary":"格隆汇8月8日丨永泰生物-B(06978.HK)公告，公司计划于2025年8月20日(星期三)举行董事会会议，藉以(其中包括)考虑及批准公司及其附属公司截至2025年6月30日止6个月中期业绩及其发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808222110973bf631&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808222110973bf631&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2557522502","title":"广生堂：乙肝创新药奈瑞可韦正开展临床III期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2557522502","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557522502?lang=zh_cn&edition=full","pubTime":"2025-08-08 20:52","pubTimestamp":1754657554,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂(300436)08月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司乙肝创新药奈瑞可韦是否对丙肝有疗效？广生堂回复：尊敬的投资者，您好。公司乙肝创新药奈瑞可韦GST-HG141目前正积极开展临床III期试验，是针对慢性乙型肝炎（CHB）抗病毒药物应答不佳患者联合治疗，其研究范围未涵盖丙型肝炎（HCV）治疗领域。感谢您对公司的关注和支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800036153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK1574","159992","BK0239","06978","BK1161"],"gpt_icon":0},{"id":"2557540960","title":"汉邦科技：创新药市场规模增长推动色谱技术需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2557540960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557540960?lang=zh_cn&edition=full","pubTime":"2025-08-08 18:03","pubTimestamp":1754647401,"startTime":"0","endTime":"0","summary":"我们理解您提及的创业药为创新药，根据沙利文及艾瑞咨询的数据，2022年中国创新药市场规模达到6,790亿元，预计2027年将达到11,170亿元，创新药物研发进程的加速，使得纯化环节在药物生产过程中的重要性愈发显著。随着抗体、重组蛋白、疫苗、核酸药物等生物药及复杂小分子药物的研发与生产需求的增长，作为分离纯化核心手段的色谱技术，其市场需求将持续提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080800031194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","688755","06978","BK1161","BK0251"],"gpt_icon":0},{"id":"2557781549","title":"港股收评：三大指数齐跌 科技股弱势 创新药大跌 黄金股普遍上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2557781549","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557781549?lang=zh_cn&edition=full","pubTime":"2025-08-08 16:24","pubTimestamp":1754641451,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HHImain","02282","MCHmain","01810","06160","000157","688981","HSImain","09688","YANG","159992","000819.SH","161726","03086","600276","TCHmain","JD","03330","HSCEI","01128","159562","HCM","ZLAB","TTTN","165316","02269","688235","TCEHY","MHImain","HSTECH","07226","BIDU","METmain","MPNGY","ALBmain","00700","ONC","01276","00981","00013","01818","09618","HSI","MIUmain","03690","BABA","06978","159871","399441"],"gpt_icon":0},{"id":"2557514131","title":"第十一批药品集采正式报量；复宏汉霖创新药获FDA批准临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2557514131","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557514131?lang=zh_cn&edition=full","pubTime":"2025-08-08 12:04","pubTimestamp":1754625857,"startTime":"0","endTime":"0","summary":"第十一批药品集采正式报量8月6日，全国医疗机构正式启动第十一批国家组织药品集中采购需求量填报工作。新闻稿指出，这是FDA首次批准针对H3 K27M突变弥漫性中线胶质瘤的全身性治疗。该药品为治疗用生物制品I类新药，目前已提交上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808120709a47c50bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808120709a47c50bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02696","BK1161","06978"],"gpt_icon":0},{"id":"2557251923","title":"又一家创新药企首度盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2557251923","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557251923?lang=zh_cn&edition=full","pubTime":"2025-08-08 10:37","pubTimestamp":1754620620,"startTime":"0","endTime":"0","summary":"01两大引擎驱动盈利乐普生物成立于2018年，是一家专注于靶向治疗和肿瘤免疫治疗的创新型生物制药企业，在七年研发投入的积累下终于开始转化为财务回报。目前，该药已获批黑色素瘤、MSI-H/dMMR实体瘤两项适应症。此次合作的首付款及近期里程碑付款为公司今年上半年贡献显著现金流。该药是乐普生物基于其Hi-TOPi平台开发的一种新型拓扑异构酶I抑制剂GPC-3 ADC候选药物，具有全球首创新药潜力，目前正在进行I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808105305a47c2cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808105305a47c2cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02157","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2557351619","title":"创新药概念探底回升 君实生物等涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557351619","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557351619?lang=zh_cn&edition=full","pubTime":"2025-08-08 10:28","pubTimestamp":1754620095,"startTime":"0","endTime":"0","summary":"人民财讯8月8日电，创新药概念股探底回升，北陆药业、联环药业、乐普医疗、君实生物、京新药业、广生堂涨超5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808102815a6d9eecd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808102815a6d9eecd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","688180","01877","06978","BK1574","600513","BK1515","BK1583"],"gpt_icon":0},{"id":"2557597828","title":"深耕宜都24年 致力研发创新药 东阳光药正式登陆港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2557597828","media":"荆楚网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557597828?lang=zh_cn&edition=full","pubTime":"2025-08-08 07:08","pubTimestamp":1754608080,"startTime":"0","endTime":"0","summary":"湖北日报讯 8月7日，广东东阳光药业股份有限公司正式登陆香港联交所主板。目前，东阳光药在广东松山湖和湖北宜都拥有两大生产基地。2025年，东阳光新药迎来全面收获期，10个项目申报生产，7个产品获批上市。同时，抗抑郁新药磷酸嘧替佐酮片、治疗肺动脉高压新药东健强即将在宜都基地完成临床样品的生产；抗流感新药东安恩已在宜都基地完成临床申报批次样品的生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808071424a47bc7fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808071424a47bc7fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","06887","HSCEI","HSTECH","BK1574"],"gpt_icon":1},{"id":"2557565670","title":"广生堂：创新药GST-HG141具有显著药效和安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2557565670","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557565670?lang=zh_cn&edition=full","pubTime":"2025-08-07 20:52","pubTimestamp":1754571132,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂08月07日在投资者关系平台上答复投资者关心的问题。公司创新药GST-HG141的Ib 期和 II期临床试验研究结果显示，GST-HG141 片具有显著药效和良好的安全性，并且起效快，在核苷类药物治疗基础上对HBV DNA具有进一步显著优势的抑制效果，且明显降低HBV pgRNA，间接体现了对HBV cccDNA的潜在有效抑制和耗竭作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080700036435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","300436","06978","BK1574","BK1161","BK0239"],"gpt_icon":0},{"id":"2557575735","title":"业绩大爆，然后暴跌了","url":"https://stock-news.laohu8.com/highlight/detail?id=2557575735","media":"财富严选","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557575735?lang=zh_cn&edition=full","pubTime":"2025-08-07 18:20","pubTimestamp":1754562044,"startTime":"0","endTime":"0","summary":"目前百济的前瞻估值约8PS，总体性价比还是比较显著的。像百济这种能够在六大洲超45个国家开展临床实验的能力，就是迈向平台性药企的重要护城河，也是国内创新药企业里非常少见的特质，跟一般卖项目的公司有本质区别。所以，我们更应该关注头部一些龙头的竞争力和性价比，目前来看前面的百济还是很不错的。当然，未来的平台药企大概不止百济一家，所以整个创新药指数也还是值得关注，等资金没有那么火爆后，我们还是可以保持介入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807182248a47abac4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807182248a47abac4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","688235","LU1969619763.USD","06978","06160","BK1588","BK1161","BK1583","LU0307460666.USD","ONC","LU2328871848.SGD","BK1500","LU0588546209.SGD"],"gpt_icon":0},{"id":"2557155622","title":"海思科最新公告：收到创新药HSK47388片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2557155622","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557155622?lang=zh_cn&edition=full","pubTime":"2025-08-07 18:11","pubTimestamp":1754561473,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称，公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，同意HSK47388片开展临床试验。该药品是公司自主研发的口服、强效、高选择性的药物，拟用于自身免疫疾病的治疗，属于化学药品1类。临床前研究显示，HSK47388具有良好的耐受性和较大的安全窗。但创新药研发周期长、风险高，存在不确定性，投资者需谨慎决策。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080700031763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","159992","BK0188","BK1161","002653","BK0033","BK0077","BK0028","BK1574"],"gpt_icon":0},{"id":"2557555114","title":"北水动向|北水成交净买入6.61亿 内资加仓芯片股及创新药概念 逢低抢筹小米(01810)超17亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557555114","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557555114?lang=zh_cn&edition=full","pubTime":"2025-08-07 17:50","pubTimestamp":1754560258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月7日港股市场，北水成交净买入6.61亿港元，其中港股通(沪)成交净卖出33.63亿港元，港股通(深)成交净买入40.24亿港元。港股通(沪)活跃成交股港股通(深)活跃成交股小米集团-W今日一度跌超5%，北水资金抢筹17.21亿港元。中芯国际、华虹半导体分别获净买入4.99亿、3.72亿港元。里昂表示，2024年美国市场收入占中芯国际总收入13%，占华虹半导体总收入10%。盈富基金遭净卖出47.19亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1326893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","LU0326950275.SGD","LU0700851271.USD","LU0572944931.SGD","XIACY","BK1526","159992","LU0823397285.USD","MIUmain","LU2488822045.USD","LU0823426308.USD","LU1961090484.USD","LU0051755006.USD","06978","LU1303224171.USD","159813","LU2257852520.SGD","LU2476274308.USD","LU0164865239.USD","LU1481107354.HKD","02800","LU0823397103.USD","LU1794554557.SGD","LU1981816686.USD","LU1023057109.AUD","LU0348783233.USD","LU1105468828.SGD","HXXD.SI","LU0823413660.USD","IE00B543WZ88.USD","BK1607","81810","LU0084288322.USD","LU0254981946.USD","LU0348825331.USD","LU0449509016.USD","LU0823413587.USD","LU1328277881.USD","BK1614","LU0918141705.HKD","LU0499858438.USD","LU0871576103.HKD","09926","LU0417516902.SGD","LU1868837565.USD","LU0314109678.HKD","01810","LU0320764599.SGD","BK1615"],"gpt_icon":1},{"id":"2557373765","title":"凯因科技：聚焦乙肝功能性治愈及免疫性疾病创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2557373765","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557373765?lang=zh_cn&edition=full","pubTime":"2025-08-07 16:00","pubTimestamp":1754553658,"startTime":"0","endTime":"0","summary":"证券之星消息，凯因科技(688687)08月07日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问贵公司在创新药方面都有哪些布局？谢谢凯因科技回复：您好，公司当前重点聚焦以创新药为核心的乙肝功能性治愈药物组合研发，同时布局免疫性疾病领域提高预防保护率与临床治愈率的创新药物管线。主要研发管线有关信息敬请关注公司定期报告及相关公告内容。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080700024610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","06978","688687","BK1161","BK1574"],"gpt_icon":0},{"id":"2557532197","title":"普洛药业：持续为全球创新药客户提供研发生产服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2557532197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557532197?lang=zh_cn&edition=full","pubTime":"2025-08-07 15:45","pubTimestamp":1754552710,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)08月07日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司目前在创新药方面有什么进展？普洛药业回复：投资者您好！目前，公司主要致力于为全球创新药客户提供全面、专业、优质、高效的研发生产服务。截至目前，公司已与600多家国内外创新药公司签订保密协议，进行中的项目已超千个，并持续保持快速增长态势。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080700021829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","000739","BK1161","159992","BK0239","BK0188","BK0060","06978"],"gpt_icon":0},{"id":"2557862534","title":"ETF收评 | A股再创阶段新高，稀土板块爆发，稀土ETF易方达、稀土ETF涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557862534","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557862534?lang=zh_cn&edition=full","pubTime":"2025-08-07 15:11","pubTimestamp":1754550689,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["512710","YANG","BK4585","516780","515890","BK4588","399006","HSCEI","515120","FDN","159883","BK4614","BK1161","512880","510300","159967","399300","BK4550","159992","512510","510880","159713","06978","000300.SH","159982","562600","159715","HSTECH","399001","161024","09996","159562","09997","BK1583","000001.SH","07226","159582","BK1222","516150","BK1100","BK1574","000688.SH","000905.SH"],"gpt_icon":0},{"id":"2557533035","title":"大行评级｜里昂：上调泰格医药目标价至62.6港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2557533035","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557533035?lang=zh_cn&edition=full","pubTime":"2025-08-07 13:17","pubTimestamp":1754543840,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0174","BK0028","03347","159992","300347","BK1161","06978","BK1576","LU1146622755.USD","BK0077","BK1583","BK0216","LU1820825898.SGD","BK1574","BK1141","159837"],"gpt_icon":0},{"id":"2557580288","title":"港股异动 | 医药股普遍走低 诺诚健华(09969.HK)跌超7% 昭衍新药(06127.HK)跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557580288","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557580288?lang=zh_cn&edition=full","pubTime":"2025-08-07 11:48","pubTimestamp":1754538521,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03347","BK1141","LU1820825898.SGD","BK0216","02171","BK0077","09969","BK0174","09939","BK1161","06127","BK0028","BK1515","BK1576","159992","BK1585","159938","BK1583","BK1574","300347","BK0239","BK1587","06978","603127","LU1146622755.USD","688428"],"gpt_icon":0},{"id":"2557530153","title":"丹诺医药IPO背后重重隐忧：9.32亿元负债压顶 54％采购依赖药明康德｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2557530153","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557530153?lang=zh_cn&edition=full","pubTime":"2025-08-07 00:42","pubTimestamp":1754498569,"startTime":"0","endTime":"0","summary":"7月30日，丹诺医药向港交所递交招股说明书，拟在港股主板上市。此次冲刺IPO，丹诺医药计划募集资金将主要用于核心产品的研究、开发、注册备案及商业化；其他候选产品的研发；建设自有生产工厂；运营资金等。丹诺医药成立于2013年，是一家专注于细菌感染及细菌代谢相关疾病领域的创新药研发公司。目前，公司已建立起一条包含七项创新资产的研发管线，涵盖多个具有潜力的治疗领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508073477938579.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508073477938579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1141","06978","09939","BK1576","BK1583","LU0052750758.USD","LU0708995583.HKD","LU2045819591.USD","BK1515","LU2242644610.SGD","BK1574","LU1046422090.SGD","LU0320764599.SGD","02359","LU2125910500.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0675},{"period":"1month","weight":0.1927},{"period":"3month","weight":0.1927},{"period":"6month","weight":0.8565},{"period":"1year","weight":0.4475},{"period":"ytd","weight":0.8565}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0405},{"period":"3month","weight":0.0871},{"period":"6month","weight":0.1763},{"period":"1year","weight":0.4716},{"period":"ytd","weight":0.2392}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":-0.027381},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026649},{"month":10,"riseRate":0.6,"avgChangeRate":0.001262},{"month":11,"riseRate":0.6,"avgChangeRate":0.007893},{"month":12,"riseRate":0.8,"avgChangeRate":0.087803}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}